schisto

The Access to Medicine (AtM) Foundation last week published a pediatric analysis of additional results from its 2021 AtM Index, finding just 7% of pharmaceutical companies’ R&D is for children under 12, despite significant gaps in treatment options for children.

The report praised GSK, Johnson & Johnson and Sanofi for being “the most active” in developing pediatric versions of products, and also named examples of drugs that “could each make a big difference” for LMICs: Eli…

The Pediatric Praziquantel Consortium announced new funding last month from Japan’s Global Health Innovative Technology (GHIT) Fund and the European & Developing Countries Clinical Trials Partnership.

The separate awards—worth a combined $9.3 million—will fund the ADOPT program, dedicated to “wide acceptance and equitable access” for a child-friendly dispersible tablet formulation of schistosomiasis drug praziquantel.

With backers including Astellas, Farmanguinhos and Merck…

Japan’s nonprofit Global Health Innovative Technology Fund (GHIT Fund) on Monday announced $13 million in drug and diagnostic investments.

Three of the seven awards will support new projects for malaria drug development and tests for schistosomiasis and Buruli ulcers. The remaining four will go toward ongoing projects to develop drugs for leishmaniasis, Chagas and soil-transmitted helminths and a rapid diagnostic for malaria.

GHIT Fund’s portfolio now includes 50 ongoing…

Germany’s Merck KGaA announced last week that it is partnering with J&J-subsidiary Janssen to develop an AI-based schistosomiasis and soil-transmitted helminths diagnostic that uses an automated microscope and data visualization tool to replace error-prone manual laboratory egg counts. The press release said prototype testing will continue throughout 2020 and “move into the clinical utility testing phase in 2021 through 2023.”

In other news, recently launched Japan-based Uniting…

Britain allocated $274 million in funding this week to provide 600 million treatments against lymphatic filariasis, onchocerciasis, schistosomiasis, visceral leishmaniasis and trachoma.

A Department for International Development press release said the support was a “vital step” towards eliminating neglected tropical diseases (NTDs), including the specific goal to rid Asia of visceral leishmaniasis by 2022.

The funds are part of Britain’s 2017 pledge of almost $450 million to…

Mentions:

Japan’s Global Health Innovative Technology Fund (GHIT) announced last week that it has appointed BMS executive Catherine Ohura as its new CEO and executive director, effective April 1. Ohura replaces founding CEO BT Slingsby, who announced last September that he would be stepping down at the end of Japan’s 2018 fiscal year (March 2019).

Last week, GHIT also announced $25.8 million in new product development funding for malaria, TB, dengue, leishmaniasis and schistosomiasis. The…

Japan’s Global Health Innovative Technology (GHIT) Fund and the European and Developing Countries Clinical Trials Partnership announced support this week for clinical trials of a schistosomiasis treatment for children. The Phase 3 study, sponsored by Merck KGaA and conducted by the Pediatric Praziquantel Consortium, will evaluate the efficacy and safety of a new tablet formulation in preschool-aged children in Kenya and Côte d’Ivoire.

Separately, Merck KGaA also announced that it has…

Mentions:

Merck KGaA announced this week that it is partnering with Baylor College of Medicine and Texas Children's Hospital Center to research, develop and manufacture new vaccines for neglected and emerging diseases.

According to Merck, the partnership will bring vaccines “through development to efficiently deliver them to societies in need.”

The partnership is focusing first on a schistosomiasis vaccine.

Mentions:

Merck KGaA announced this week that it is forming a public-private partnership with the Australian Institute of Tropical Health and Medicine and Baylor College of Medicine, Texas to help develop new schistosomiasis diagnostics through identifying biomarkers for the disease. The company will invest $150,000 per year over the next three years to support research efforts.

Merck KGaA said its announcement is designed to help celebrate the 10th anniversary of its Praziquantel Donation…

Japan’s Global Health Innovation Technology Fund (GHIT Fund) announced 11 new investments in infectious disease R&D and product development last week totaling $23 million.

The public-private partnership’s latest investments support work on Chagas disease, cryptosporidiosis, dengue, leishmaniasis, malaria and schistosomiasis. Among the grant recipients is a Phase 3 clinical trial evaluating a child-friendly formulation of praziquantel for schistosomiasis. GHIT also awarded $600,000…